Prostate Cancer: A Brief History and the Discovery of Hormonal Ablation Treatment

Lytton, Bernard

doi:10.1016/s0022-5347(05)66228-3

Cited by 33 publications

(37 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…He later concluded -on the basis of the effects of castration -that there was a direct connection between the testes and secondary sex organs, 5 . Later, in the nineteenth century, a number of reports describing a link between the testes and prostate gland were also published 6 . In 1893, the Philadelphia surgeon W. White measured changes in the size of the prostate gland in dogs after castration, reporting atrophy of glandular elements and a decrease in prostate weight 7 .…”

Section: Androgen-ablation Therapymentioning

confidence: 99%

“…He advocated castration as a treatment for urinary obstruction disorders. Numerous reports on the efficacy of castration therapy followed, with mixed results that might have been due to the lack of distinction between cancer and benign prostatic hyperplasia 6 .…”

Section: Androgen-ablation Therapymentioning

confidence: 99%

Section: Prostatectomymentioning

confidence: 99%

“…Historically, surgery for prostate cancer was initially performed to relieve symptoms of urinary obstruction 6 . Before the twentieth century, there were sporadic reported cases of surgical removal of obstructive prostatic masses 6 . There was, however, no systematic technique for removal of the prostate until the pioneering work of Hugh Hampton Young, who, in 1904, at the Johns Hopkins Hospital, performed the first radical perineal prostatectomy 40 (see TIMELINE).…”

Section: Prostatectomymentioning

confidence: 99%

See 3 more Smart Citations

A history of prostate cancer treatment

2002

View full text Add to dashboard Cite

The increased incidence of prostate cancer has led to remarkable changes in diagnosis and treatment over the past century. What were the first ways in which prostate cancer was treated, and how did these evolve into the variety of therapeutic strategies from which patients have to choose today?In 1853, J. Adams, a surgeon at The London Hospital, described the first case of prostate cancer, which he discovered by histological examination 1 . Adams noted in his report that this condition was "a very rare disease". Remarkably, 150 years later, prostate cancer has become a significant health problem. In the United States, it is the most commonly diagnosed cancer in men, with 180,000 new cases and about 31,000 deaths occurring annually 2 . This dramatic increase in the number of prostate cancer cases can be attributed to several causes. First, prostate cancer was not differentiated from other types of urinary obstruction until the early 1900s. Second, the incidence of prostate cancer increases more rapidly with age than any other cancer type 2 . The number of cases has risen as the average life expectancy has increased over the past century. Third, the increased incidence seems to be, in some way, related to the 'Western' lifestyle: the incidence of clinical prostate cancer is significantly lower in Asian populations, compared with Western populations 3 , and it

show abstract

Section: Androgen-ablation Therapymentioning

confidence: 99%

Section: Androgen-ablation Therapymentioning

confidence: 99%

Section: Prostatectomymentioning

confidence: 99%

Section: Prostatectomymentioning

confidence: 99%

See 2 more Smart Citations

A history of prostate cancer treatment

2002

View full text Add to dashboard Cite

show abstract

“…Although surgical resection and radiotherapy are potentially curative for localized (organ-confined) disease, conventional chemotherapy and radiotherapy still have limited efficacy against advanced disease (Wang and Waxman, 2000). Androgen ablation often leads to symptomatic improvement in patients with advanced disease, but progression to hormone refractory disease is usually inevitable (Lytton, 2001). Therefore, new approaches to therapy of prostate cancer are greatly needed, not only as alternatives to conventional treatment for adenocarcinoma but also for chemoprevention for patients with prostate cancer precursor lesions, such as high grade prostatic intraepithelial neoplasia, or small organconfined invasive tumors, as well as for patients with advanced and metastatic prostate cancer.…”

mentioning

confidence: 99%

Primary culture model of peroxisome proliferator‐activated receptor γ activity in prostate cancer cells

Iyengar

Roberts

et al. 2003

Journal Cellular Physiology

View full text Add to dashboard Cite

BRL 49653 (rosiglitazone) is a thiazolidinedione anti-diabetic drug that activates the nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARg). Pilot clinical trials have shown evidence of therapeutic activity of PPARg agonists against prostate cancer. To more effectively use PPARg ligands to treat this common and generally chemo-resistant type of cancer, it will be necessary to better understand the nature of PPARg activity in prostate cancer cells. Tumor suppressor effects of activation of PPARg may include suppression of growth and/or induction of differentiation or apoptosis. We investigated responses of primary cultures of human prostatic cancer cells to BRL 49653. PPARg was expressed in all of the cell strains examined. BRL 49653 caused dose-and time-dependent growth inhibition that was associated with increased expression of the transcription repressor, transforming growth factor b-stimulated clone 22 (TSC-22), and markedly increased expression of the secretory differentiation-associated gene adipophilin. Adipocyte-type fatty acid binding protein (aFABP), neutrophil gelatinase-associated lipocalin (NGAL), glycerol kinase (GyK), and b-catenin, which are regulated by PPARg ligands in certain other types of cells, were not regulated by BRL 49653 in prostate cells. Upregulation of adipophilin coincided with morphological changes and the appearance of cytoplasmic vacuoles with ultrastructural features of secondary lysosomes. These results extend previous studies with established cancer cell lines and show that PPARg agonists can inhibit proliferation and modulate expression of secretory-associated genes in primary cultures of prostate cancer cells, further warranting consideration of these agents as pro-differentiating chemotherapeutic or chemoprevention agents for the treatment of prostate cancer.

show abstract

Prostate Cancer

2022

Fundamentals of Cancer Detection, Treatment, and Prevention

View full text Add to dashboard Cite

Prostate Cancer: A Brief History and the Discovery of Hormonal Ablation Treatment

Cited by 33 publications

References 13 publications

A history of prostate cancer treatment

A history of prostate cancer treatment

Primary culture model of peroxisome proliferator‐activated receptor γ activity in prostate cancer cells

Prostate Cancer

Contact Info

Product

Resources

About